Enhancing Research Productivity by 30% Arcturus Therapeutics is an industry leader in RNA medicines. The company’s aim is to use its versatile, breakthrough RNA platform to develop novel therapies for rare diseases for which there are no adequate treatments. Arcturus collaborates with Janssen Pharma- ceuticals and Ultragenyx Pharmaceutical. PRIOR CHALLENGES 1 / Lack of standardized molecular design tools hindered ability to collaborate. 2 / Legacy ELN was cumbersome and led to low scientist usage. It took an average of 10 days for experimental data to make it into the system, if at all. 3 / No standard data store and sequence repository scattered data and prevented institutional knowledge capture. KEY BENEFITS 1 / Molecular Biology Collaboration With Benchling's unified cloud plat

Join for free to read